8-K: Veeva Systems Exceeds Q4, FY26 Expectations with Strong Growth

Veeva Systems reported robust fourth quarter and fiscal year 2026 results, surpassing guidance with significant revenue and profit growth driven by strong execution and AI innovation.

Summary

• Total revenues for the fourth quarter were $836.0 million, an increase of 16% year over year.
• Subscription revenues for the fourth quarter were $707.7 million, an increase of 16% year over year.
• GAAP operating income for the fourth quarter was $245.9 million, an increase of 30% year over year.
• Non-GAAP operating income for the fourth quarter was $366.5 million, an increase of 19% year over year.
• GAAP net income for the fourth quarter was $244.2 million, an increase of 25% year over year.
• Non-GAAP net income for the fourth quarter was $346.1 million, an increase of 20% year over year.
• Fully diluted GAAP net income per share for the fourth quarter was $1.45, compared to $1.18 one year ago.
• Fully diluted non-GAAP net income per share for the fourth quarter was $2.06, compared to $1.74 one year ago.
• Total revenues for fiscal year 2026 were $3,195.3 million, an increase of 16% year over year.
• Subscription revenues for fiscal year 2026 were $2,684.2 million, an increase of 17% year over year.
• GAAP operating income for fiscal year 2026 was $916.4 million, an increase of 33% year over year.
• Non-GAAP operating income for fiscal year 2026 was $1,433.8 million, an increase of 24% year over year.
• GAAP net income for fiscal year 2026 was $908.9 million, an increase of 27% year over year.
• Non-GAAP net income for fiscal year 2026 was $1,352.5 million, an increase of 24% year over year.
• Fully diluted GAAP net income per share for fiscal year 2026 was $5.44, compared to $4.32 one year ago.
• Fully diluted non-GAAP net income per share for fiscal year 2026 was $8.10, compared to $6.60 one year ago.
• Veeva finished the year with a total of 1,552 customers, including 1,196 in Veeva R&D and Quality Solutions and 767 in Veeva Commercial Solutions.
• Achieved its $3 billion revenue run rate in early 2025.
• Released the first Veeva AI Agents for CRM and commercial content, with more projects underway and additional agents planned for release across other major application areas throughout 2026.
• Veeva LIMS is on track for its first top 20 biopharma go-live at two manufacturing sites in 2026.
• More than 125 customers are live on Vault CRM, including 2 top 20 biopharmas in major markets, with many more on track to go live in 2026.
• Ended the year with 10 top 20 biopharmas committed to Vault CRM globally and expects about 14 of the top 20 to commit.

Sentiment

Score: 9

Explanation: StockSavvy.ai views this as a very strong report, demonstrating consistent growth, exceeding guidance, and outlining a clear strategic path with significant AI innovation and customer expansion in a critical industry.

Positives

• Achieved strong total revenue growth of 16% year over year for both Q4 and fiscal year 2026, reaching $836.0 million and $3,195.3 million respectively.
• Subscription revenues demonstrated robust growth of 16% in Q4 and 17% for fiscal year 2026, totaling $707.7 million and $2,684.2 million.
• Operating income saw significant increases, with GAAP operating income up 30% in Q4 to $245.9 million and 33% for FY26 to $916.4 million.
• Non-GAAP operating income also grew substantially, up 19% in Q4 to $366.5 million and 24% for FY26 to $1,433.8 million.
• Net income showed strong performance, with GAAP net income up 25% in Q4 to $244.2 million and 27% for FY26 to $908.9 million.
• Non-GAAP net income increased 20% in Q4 to $346.1 million and 24% for FY26 to $1,352.5 million.
• Fourth quarter financial results exceeded guidance across the board, indicating strong operational execution.
• Reached a significant milestone of $3 billion revenue run rate in early 2025.
• Expanded customer base to 1,552, demonstrating continued market penetration and customer success.
• Driving innovation with deeply integrated, industry-specific AI, with initial Veeva AI Agents for CRM and commercial content already released and more planned for 2026.
• Strengthened leadership in R&D and Quality with key wins, including a top 20 biopharma selecting Veeva RTSM as their enterprise standard and momentum in Safety solutions.
• Veeva LIMS is on track for its first top 20 biopharma go-live at two manufacturing sites in 2026, indicating progress in newer application areas.
• Accelerating the industry's move to agentic CRM with over 125 customers live on Vault CRM, including 2 top 20 biopharmas, and expects about 14 of the top 20 to commit globally.
• Crossix experienced a breakout year with strong growth in Measurement and Audiences.
• Management expressed confidence in the trajectory toward a $6 billion revenue run rate target by 2030.

Risks

• Issues related to the performance, availability, security, or privacy of products could negatively impact financial performance.
• Competitive factors may affect market share and pricing power.
• Customer decisions and priorities can influence demand for solutions.
• Developments that impact the life sciences industry, such as regulatory, funding, or policy changes, could affect business operations.
• General macroeconomic and geopolitical events, including changes in trade policy, inflationary pressures, currency exchange fluctuations, interest rates, and geopolitical conflicts, pose risks.
• Challenges in hiring, retaining, and adequately compensating talented employees could impact operational capacity and innovation.

Future Outlook

Veeva is providing guidance for its fiscal first quarter ending April 30, 2026, with total revenues projected between $855 million and $858 million, non-GAAP operating income between $378 million and $381 million, and non-GAAP fully diluted net income per share between $2.13 and $2.14. For the fiscal year ending January 31, 2027, total revenues are expected to be between $3,585 million and $3,600 million, non-GAAP operating income about $1,590 million, and non-GAAP fully diluted net income per share approximately $8.85. The company maintains its trajectory toward a $6 billion revenue run rate target by 2030.

Management Comments

• "The agentic transformation underway represents a substantial opportunity for Veeva and life sciences. With our core systems of record spanning the industrys most critical functions and unique datasets, we can deliver industry-specific AI deeply integrated into our applications." CEO Peter Gassner
• "Our progress with Veeva AI and continued strong execution in Commercial Cloud, Development Cloud, and Quality Cloud will create significant value for the industry." CEO Peter Gassner
• "Financial results in the fourth quarter exceeded our guidance across the board and capped off a year of durable, profitable growth." CFO Brian Van Wagener
• "As we look ahead, strong momentum and operational discipline give us confidence in our trajectory toward our $6 billion revenue run rate target by 2030." CFO Brian Van Wagener

Industry Context

StockSavvy.ai notes that Veeva's focus on deeply integrated, industry-specific AI solutions positions it strongly within the life sciences cloud market, leveraging its existing systems of record and specialized datasets. This strategy aligns with broader industry trends towards AI-driven efficiency and compliance in highly regulated sectors, potentially widening its competitive moat against generalist cloud providers. The continued expansion of its customer base and product offerings across R&D, Quality, and Commercial solutions reinforces its dominant position in providing critical infrastructure for the global life sciences industry.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, exceeding guidance, robust growth in key metrics, and a clear long-term vision with AI innovation.
• Customers: Positive impact through continued product excellence, expansion of AI-integrated solutions (Veeva AI Agents, Vault CRM), and strengthening partnerships in R&D, Quality, and Commercial solutions.
• Employees: Positive impact from a growing, innovative company with strong financial health, potentially leading to continued investment in talent and career opportunities.

Next Steps

• Release additional Veeva AI agents across other major application areas throughout 2026.
• Achieve first top 20 biopharma go-live for Veeva LIMS at two manufacturing sites in 2026.
• Bring many more customers live on Vault CRM in 2026.
• Work towards approximately 14 of the top 20 biopharmas committing to Vault CRM globally.
• Progress towards the $6 billion revenue run rate target by 2030.

Key Dates

Recommendation

The company delivered exceptional Q4 and full fiscal year 2026 results, significantly exceeding its own guidance. Strong double-digit revenue and profit growth, coupled with strategic advancements in AI and continued customer expansion across its core platforms (Commercial Cloud, Development Cloud, Quality Cloud), demonstrate robust operational execution and a compelling long-term growth trajectory towards its $6 billion revenue target by 2030. The deep integration of industry-specific AI into its applications further solidifies its competitive advantage in the life sciences sector.

Keywords

Veeva Systems, VEEV, Life Sciences, Cloud Solutions, Financial Results, Q4 2026, Fiscal Year 2026, Subscription Revenue, Operating Income, Net Income, AI, Commercial Cloud, Development Cloud, Quality Cloud, Vault CRM, Crossix, Biopharma, Healthcare Technology, Software as a Service, SaaS